Fianlimab

弗安利单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameFianlimab
Drug Alias NameREGN-3767
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitorsImmunomodulators
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsSkin MelanomaUrinary Bladder NeoplasmsFallopian Tube Neoplasms +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of California IrvineThe University Of ChicagoColumbia University +[4] 
Inactive CompaniesN/A
Active IndicationsSkin MelanomaUrinary Bladder NeoplasmsFallopian Tube Neoplasms +[15] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A